In silico evaluation of potential penicillin-binding protein 2 (PBP2) inhibitors from Borassus flabellifer haustorium against cephalosporin-resistant Neisseria gonorrhoeae
- 1Department of Integrative Biology, School of Bio Sciences and Technology, Vellore Institute of Technology , , ,
Abstract
Background: The emergence of cephalosporin-resistant Neisseria gonorrhoeae strains, encoding altered Penicillin-Binding Protein 2 (PBP2), has become a major global public health concern. The increasing prevalence of antimicrobial resistance necessitates the development of novel antimicrobial agents. In the present study, phytocompounds derived from the haustorium of Borassus flabellifer L. were investigated as potential inhibitors of PBP2 using an integrated in silico approach.
Methodology: Phytochemical profiling of the methanol, ethyl acetate and hexane extracts of white spongy palmyra haustorium was performed using GC–MS and the identified compounds were subsequently evaluated for molecular docking, ADMET analysis and molecular dynamics simulation.
Results: A total of 69 compounds were identified and subjected to molecular docking against the transpeptidase domain of PBP2. The docking analysis revealed predicted binding affinities, ranging from −4.5 to −9.7 kcal/mol. The top ten compounds were subsequently evaluated for their ADMET and drug-likeness properties. Among these, 5-(4-nitrophenyl)-1,3,4-oxadiazol-2(5H)-one and 1,2,4-triazol-3-amine, 5-(1,3,5-trimethyl-4-pyrazolyl)amino, demonstrated comparatively favourable pharmacokinetic properties and balanced predicted ADMET profile. Furthermore, the stability of the complexes was assessed for a time period of 100 ns using molecular dynamics simulation. RMSD, RMSF, Rg, SASA, and hydrogen bonds were examined to evaluate protein-ligand interactions throughout the time frame. Principal component analysis and free energy landscape studies further supported ligand-induced stabilization of the PBP2 structure. MM-PBSA revealed favourable interaction energies of −19.11 ± 2.29 kJ/mol and −11.16 ± 2.34 kJ/mol for the two selected compounds, respectively. Among them, 5-(4-nitrophenyl)-1,3,4-oxadiazol-2(5H)-one demonstrated comparatively greater binding stability and thermodynamic favourability.
Conclusion: These findings suggest that 5-(4-nitrophenyl)-1,3,4-oxadiazol-2(5H)-one could serve as a promising lead molecule for the development of new therapeutics against drug-resistant gonococcal infections and necessitate further experimental validation.
Related
- Direct Oral Challenge for Penicillin Allergy: A Hospital Implementation Evaluation Via the International Network of Antibiotic Allergy Nations (iNAAN) Study
- Design and evaluation of probe-capture sequencing for clinical Neisseria gonorrhoeae specimens
- Pooled prevalence of third-generation cephalosporin resistance among Escherichia coli bloodstream isolates in Southeast Asia: protocol for systematic review and meta-analysis.
- Economic evaluation of SGLT2 inhibitors and GLP-1 receptor agonists in Thai patients with type 2 diabetes and established atherosclerotic cardiovascular disease
- Evaluation of 6-substituted coumarins as SARS-CoV-2 main protease inhibitors: enzymatic, cellular, and computational insights.
BibTeX
@article{rajasekaran2026silico,
title = {{In silico evaluation of potential penicillin-binding protein 2 (PBP2) inhibitors from Borassus flabellifer haustorium against cephalosporin-resistant Neisseria gonorrhoeae}},
author = {Udhaya Rajasekaran and T. B. Sridharan},
journal = {Frontiers in pharmacology},
year = {2026},
month = oct,
doi = {10.3389/fphar.2026.1918221},
url = {https://europepmc.org/article/PMC/PMC13690551},
note = {CC BY},
}
RIS
TY - JOUR
TI - In silico evaluation of potential penicillin-binding protein 2 (PBP2) inhibitors from Borassus flabellifer haustorium against cephalosporin-resistant Neisseria gonorrhoeae
AU - Udhaya Rajasekaran
AU - T. B. Sridharan
PY - 2026
DA - 2026/10/09
JO - Frontiers in pharmacology
DO - 10.3389/fphar.2026.1918221
UR - https://europepmc.org/article/PMC/PMC13690551
AB - Background: The emergence of cephalosporin-resistant Neisseria gonorrhoeae strains, encoding altered Penicillin-Binding Protein 2 (PBP2), has become a major global public health concern. The increasing prevalence of antimicrobial resistance necessitates the development of novel antimicrobial agents. In the present study, phytocompounds derived from the haustorium of Borassus flabellifer L. were investigated as potential inhibitors of PBP2 using an integrated in silico approach. Methodology: Phytochemical profiling of the methanol, ethyl acetate and hexane extracts of white spongy palmyra haustorium was performed using GC–MS and the identified compounds were subsequently evaluated for molecular docking, ADMET analysis and molecular dynamics simulation. Results: A total of 69 compounds were identified and subjected to molecular docking against the transpeptidase domain of PBP2. The docking analysis revealed predicted binding affinities, ranging from −4.5 to −9.7 kcal/mol. The top ten compounds were subsequently evaluated for their ADMET and drug-likeness properties. Among these, 5-(4-nitrophenyl)-1,3,4-oxadiazol-2(5H)-one and 1,2,4-triazol-3-amine, 5-(1,3,5-trimethyl-4-pyrazolyl)amino, demonstrated comparatively favourable pharmacokinetic properties and balanced predicted ADMET profile. Furthermore, the stability of the complexes was assessed for a time period of 100 ns using molecular dynamics simulation. RMSD, RMSF, Rg, SASA, and hydrogen bonds were examined to evaluate protein-ligand interactions throughout the time frame. Principal component analysis and free energy landscape studies further supported ligand-induced stabilization of the PBP2 structure. MM-PBSA revealed favourable interaction energies of −19.11 ± 2.29 kJ/mol and −11.16 ± 2.34 kJ/mol for the two selected compounds, respectively. Among them, 5-(4-nitrophenyl)-1,3,4-oxadiazol-2(5H)-one demonstrated comparatively greater binding stability and thermodynamic favourability. Conclusion: These findings suggest that 5-(4-nitrophenyl)-1,3,4-oxadiazol-2(5H)-one could serve as a promising lead molecule for the development of new therapeutics against drug-resistant gonococcal infections and necessitate further experimental validation.
SN - 1663-9812
ER -